How many insider trades does FilingIQ track for URGN?

FilingIQ tracks 251 Form 4 insider transactions for URGN (UroGen Pharma Ltd.), covering filings from Nov 27, 2017 onwards. 1 of those were filed in the last 90 days.

Are URGN insiders net buyers or net sellers?

Across the full Form 4 history for URGN, 9 transactions (4%) were open-market purchases and 94 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does URGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is URGN in?

UroGen Pharma Ltd. (URGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $969.41M.

URGN insider trading

Healthcare

UroGen Pharma Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

251

Last 90 days

Buys / sells

4% / 37%

Market cap

$969.41M

About UroGen Pharma Ltd.

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Company website: www.urogen.com

URGN insider activity at a glance

FilingIQ has scored 251 insider transactions for URGN since Nov 27, 2017. The most recent filing in our index is dated May 8, 2026.

Across the full history, 9 open-market purchases and 94 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on URGN insider trades is 57.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live URGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for URGN?: FilingIQ tracks 251 Form 4 insider transactions for URGN (UroGen Pharma Ltd.), covering filings from Nov 27, 2017 onwards. 1 of those were filed in the last 90 days.
Are URGN insiders net buyers or net sellers?: Across the full Form 4 history for URGN, 9 transactions (4%) were open-market purchases and 94 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does URGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is URGN in?: UroGen Pharma Ltd. (URGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $969.41M.

Methodology & sources

Every URGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.